SPARINGVISION
SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases. SparingVision is developing SPVN06, a gene-independent treatment for retinitis pigmentosa, the most common inherited retinal degeneration. There is currently no treatment to treat all genetic forms of this rare retinal disease that leads to blindness and affects nearly 2 million people worldwide.
SPARINGVISION
Industry:
Biotechnology Health Care Life Science
Founded:
2016-01-01
Address:
Paris, Ile-de-France, France
Country:
France
Website Url:
http://www.sparingvision.com
Total Employee:
1+
Status:
Active
Contact:
+33(0)1 43 46 20 60
Email Addresses:
[email protected]
Total Funding:
52.74 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Font Awesome
Similar Organizations
Alkermes
Alkermes is a biotechnology company that develops, manufactures and commercializes medicines for the treatment of chronic diseases.
Ribon Therapeutics
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Current Advisors List
Current Employees Featured
Founder
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-04-20 | GAMUT Therapeutics | GAMUT Therapeutics acquired by SparingVision | N/A |
Investors List
Intellia Therapeutics
Intellia Therapeutics investment in Corporate Round - SparingVision
Jeito Capital
Jeito Capital investment in Venture Round - SparingVision
Foundation Fighting Blindness
Foundation Fighting Blindness investment in Venture Round - SparingVision
4BIO Capital
4BIO Capital investment in Venture Round - SparingVision
Ysios Capital
Ysios Capital investment in Venture Round - SparingVision
UPMC Enterprises
UPMC Enterprises investment in Venture Round - SparingVision
Bpifrance
Bpifrance investment in Venture Round - SparingVision
Key Employee Changes
| Date | New article |
|---|---|
| 2021-12-09 | SparingVision Strengthens Leadership Team with the Appointment of Dr Mehdi Gasmi as Chief Operating Officer |
Official Site Inspections
http://www.sparingvision.com Semrush global rank: 9.41 M Semrush visits lastest month: 160
- Host name: 25.26.205.92.host.secureserver.net
- IP address: 92.205.26.25
- Location: Germany
- Latitude: 51.4476
- Longitude: 7.0122
- Timezone: Europe/Berlin
More informations about "SparingVision"
Home - SparingVision
Apr 22, 2025 SparingVision Receives FDA Support to Initiate Phase II trial of SPVN06 in Geographic Atrophy Secondary… April 22, 2025 Content Team 2025-04-22T13:00:25+02:00 …See details»
SparingVision - Crunchbase Company Profile & Funding
SparingVision may be growing as indicated by a series of financial and operational developments. The company successfully raised a significant …See details»
People - SparingVision
Dr. Chung was appointed Chief Medical Officer of SparingVision in February 2021. He leads the clinical development and research of our lead programs SPVN06 and SPVN20, and oversees …See details»
SparingVision - Org Chart, Teams, Culture & Jobs - The Org
SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases. SparingVision is …See details»
SparingVision - LinkedIn
SparingVision is a genomic medicines company, translating pioneering science into vision-saving treatments. Founded to advance over 20 years of world-leading ophthalmic research from its ...See details»
SparingVision's Leadership Team - Team members and org chart
SparingVision's Leadership Team includes Myriam Marussig and 5 others. Team members. Dan Chung. CMO. Florence Lorget. CDSO. Myriam Marussig. COO. Rajiv Gangurde. CTO. …See details»
SparingVision - Contacts, Employees, Board Members, Advisors
SparingVision is a biotechnology company developing genomic medicines for the treatment of blinding inherited retinal diseases. ... Experience the new Crunchbase, powered by AI . …See details»
SparingVision 2025 Company Profile: Valuation, …
SparingVision General Information Description. Developer of a medical therapy designed to treat Retinitis Pigmentosa which is part of Inherited Retinal Diseases. The company's offerings include a drug candidate to treat retinitis pigmentosa, …See details»
SparingVision Company Profile - Office Locations, Competitors
SparingVision is a biotechnology company focused on the development of therapies for the treatment of blinding inherited retinal diseases. It offers SPVN06, a gene-independent drug …See details»
News & Media - SparingVision
Apr 22, 2025 SparingVision Announces Presentation of SPVN06 Safety Data at the Macula Society 48th Annual Meeting … February 13, 2025 Read More. Content Team 2025-02-13T13:45:09+01:00. Press Release. SparingVision …See details»
SparingVision Company Profile Funding & Investors - YourStory
SparingVision is a genomic medicines company, translating pioneering science into vision-saving treatments. Founded to advance over 20 years of world-leading ophthalmic research from its ...See details»
Dr Daniel C. Chung appointed as Chief Medical Officer of …
Paris, February 04, 2021 – SparingVision (the “Company”), a genomic medicine company developing vision saving treatments for ocular diseases, today announces the appointment of …See details»
A Day in the Life of Biotech Startup SparingVision - servier.com
Dec 19, 2024 SparingVision’s approach: Genotype-Independent Gene Therapy. Gene therapy is an innovative medical strategy that uses DNA as a drug. The goal is to address a mutation (a …See details»
SparingVision - Funding, Financials, Valuation & Investors
SparingVision is a biotechnology company developing genomic medicines for the treatment of blinding inherited retinal diseases. New. Resources. Advanced Search. ... How much funding …See details»
Renowned Pioneers in Ophthalmology Join SparingVision’s …
Jan 29, 2021 SparingVision, a genomic medicine company developing vision saving treatments for ocular diseases, today announces the strengthening of its Scientific Advisory Board …See details»
Company: SparingVision
SparingVision is a gene therapy focused company, that develops medicines for the treatment of ocular diseases. The company is currently developing multiple pre-clinical programmes, …See details»
SparingVision Receives Authorization to Launch US Clinical Trial …
Dec 2, 2022 SparingVision, a French company developing therapies for ocular conditions including inherited retinal diseases, has received authorization from the US Food & Drug …See details»
SparingVision Announces Presentation of SPVN06 Safety Data at …
Feb 13, 2025 SparingVision is a genomic medicines company with a mission to translate pioneering science into vision saving treatments. Leveraging its unparalleled understanding of …See details»
Builders Vision | Builders Vision Announces Noelle Laing as New …
3 days ago Chicago, IL – Today, Builders Vision announced that Noelle Laing, CFA, has been promoted to a new role as the sole Chief Investment Officer (CIO) of Builders …See details»
SparingVision Selects Second Target in Strategic Collaboration …
Sep 26, 2023 SparingVision selected a first target in early 2022, with the corresponding product currently in the research phase. Today’s update highlights the identification of a second …See details»